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access article under the CC BY-NC-NDSummary Background: Pseudoangiomatous stromal hyperplasia (PASH) is a benign mesen-
chymal proliferative lesion of the breast. Owing to the rarity of PASH, the pathogenesis, clin-
ical manifestation, and optimal treatment of this condition remain unclear. We aimed to
clarify the appropriate management of PASH.
Methods: We performed a retrospective analysis of the clinicopathological data of 66 cases
with a diagnosis of PASH, confirmed by core needle biopsy (CNB) or surgical excision at Sever-
ance Hospital between 2000 and 2016. The primary endpoint was pathologic results after sur-
gical excision of the lesion that confirmed PASH by CNB. The secondary endpoint was
progression after the first treatment.
Result: The median age of patients was 41 years (range, 14e61 years). Findings on medical im-
aging were nonspecific. CNB was performed in 61 cases, with a diagnosis of PASH confirmed in
39 cases (63.9%). No malignant or premalignant cells directly arising from PASH were identified
after surgical excision that confirmed PASH via CNB. The progression rate after the first treat-
ment was 16.6%, with lesion size, enlargement of palpable mass size, and a diagnosis other
than PASH on CNB being factors associated with progression.
Conclusion: CNB is sufficient to confirm PASH what is necessary for an abnormal imaging or sus-
picious physical examination finding. Surgical excision is not necessarily indicated to rule out
occult malignancy after a diagnosis of PASH. Close monitoring or surgical excision are required
to manage large lesions (>3 cm) or progressive growth of a PASH lesion.reast Surgery, Department of Surgery, Yonsei University College of Medicine, 50 Yonsei-ro, Seodae-
rea. Fax: þ82 2 2228 4140.
c, youngup.cho@gmail.com (Y.U. Cho).
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Pseudoangiomatous stromal hyperplasia (PASH) is a benign
mesenchymal proliferation of myofibroblasts of the breast.
Due to the rarity of PASH, its pathogenesis, clinical pre-
sentation, diagnosis, and proper management are poorly
understood.
Although PASH mainly occurs in perimenopausal women,
the incidence of PASH has also been reported in men
associated with gynecomastia, and in menopausal women
on hormone replacement therapy.1 The pattern of inci-
dence of PASH supports a hormonal etiology. It has been
postulated that PASH results from activation of stromal
myofibroblasts by endogenous and exogenous hormone
stimulation, which results in excessive secretion of
collagen.2 The collagenous stroma comprises spindle cells,
containing an anastomosing slit-like pseudovascular space,
without red blood cells.3 This pseudovascular space is the
most typical histological finding of PASH, especially in its
simple form.4 PASH lesions are usually located in interlob-
ular or intralobular stroma, have a low mitotic count, and
none-to-mild nuclear atypia.5 These are specific distinctive
features of PASH that differentiate it from a low-grade
angiosarcoma or phyllodes tumor.6
Clinically, PASH can mimic a fibroadenoma.6 In addition,
PASH can coexist with other breast lesions7 and even pre-
sent as significantly enlarged breast.8 On imaging, PASH
presents with benign features that are generally nonspe-
cific.9 PASH is most commonly diagnosed incidentally during
histological examination of another benign or malignant
lesion.10 With regard to treatment, surgical excision has
traditionally been recommended to confirm the absence of
occult malignancy and to prevent progression or recur-
rence.11 The management of PASH has become significantly
standardized in recent years. The American Society of
Breast Surgeons does not recommend routine excision;
however, supportive data are limited.12 Furthermore, there
is currently no statistical evidence of disease progression or
credible evidence for the appropriate management of
PASH.13
Accordingly, our aim in this study was to review the
clinical, radiological, and histological features of PASH and
recommend an appropriate strategy for its diagnosis and
treatment.
2. Material and methods
2.1. Patient selection
We conducted a retrospective review of patients who were
diagnosed with PASH at Severance Hospital (Seoul, South
Korea), between January 2000 and December 2016. The
inclusion criterion was a diagnosis of PASH confirmed bycore needle biopsy (CNB) and/or surgical excision. Patients
with a follow-up of less than six months after confirmation
of the diagnosis were excluded. The following clinicopath-
ological variables were extracted from the medical records
for analysis: menopausal status for women; breast disease
history; medication history; chief complaints; findings on
physical examination; findings on imaging [mammography
(MMG), ultrasonography (US), and/or magnetic resonance
imaging (MRI)]; treatment methods; pathologic reports; and
follow-up data.
This study was approved by the Institutional Review
Board of the Severance Hospital, Yonsei University Health
System (2018-0878-001). The requirement for patient con-
sent was waived owing to the retrospective design of our
study and the use of de-identified data.
2.2. Clinicopathological characteristics of PASH
Medical imaging was performed by experienced radiolo-
gists, with images recorded using the breast image and
reporting data system (BI-RADS), which was developed by
the American College of Radiology. CNB was performed
under US guidance using a 14-gauge automated core needle
to obtain tissue samples. CNB was indicated for patholog-
ical confirmation of the diagnosis in patients with suspicious
findings on imaging (a BI-RADS grade 4a). All pathological
data were interpreted by pathologists specialized in breast
diseases.
The first treatment option was based on clinical mani-
festation and findings on images and pathological results,
and could include observation, vacuum-assisted excision
(VAE), or surgical excision. VAE was performed under either
stereotactic or US guidance using an 8- or 11-gauge needle.
Progression was defined as an increase in the volume of a
lesion that had confirmed PASH on following image studies
after diagnosis or the first treatment.
2.3. Data and statistical analysis
For analysis, patients were divided into the CNB-positive
group (patients with PASH confirmed by CNB), CNB-negative
group (patients with other lesions confirmed by CNB) and
diagnosed by mastectomy group (patients who had mas-
tectomy without pathologic confirmation) (Fig. 1). We
analyzed the pathologic results after surgical excision or
VAE in the CNB-positive group to evaluate for occult ma-
lignancy with PASH lesion. Subsequently, all PASH cases
were divided into the progression and non-progression
groups. Clinicopathological and treatment variables were
compared between the two groups using the
ManneWhitney U test for quantitative variables (without a
normal distribution) and a chi-squared test or the Fisher’s
exact test for nominal data. A binary logistic regression

































FAH with PASH (N=1)
FCC with PASH (N=2)
IDP with PASH (N=1) PASH (N=1)
FA with PASH (N=1)
FAH with PASH (N=1)
FA with PASH (N=1)
FCC with PASH (N=1)
IDP with PASH (N=1)
ADH with PASH (N=1)
Figure 1 Flowchart of management strategies including follow-up data and pathologic diagnosis of progression group. PASH
pseudoangiomatous stromal hyperplasia, CNB core needle biopsy, VAE vacuum-assisted excision, FAH Fibroadenomatoid hyper-
plasia, FCC Fibrocystic change, IDP intraductal papilloma, FA Fibroadenoma, ADH atypical ductal hyperplasia. a confirmed PASH by
initial CNB, b confirmed other lesion by initial CNB, these group confirmed PASH by VAE or excision after CNB, c confirmed PASH by
mastectomy except pathologic confirmation.
Pseudoangiomatous stromal hyperplasia does not require surgery 737predictive factors of PASH progression after the first
treatment. The multivariate analysis was adjusted for
confounding variables that were significant in the univari-
ate analyses. Due to the small sample size and therefore
low statistical power of our model, we calculated the
discriminative effect of our multivariate logistic analysis for
PASH progression using the area under the receiver oper-
ating characteristics (ROC) curve. All statistical tests were
two-sided, with a P-value <0.05 considered significant.
Analyses were performed using IBM SPSS v. 23.0 (Armonk,
NY, USA).
3. Results
3.1. Characteristics of patients
Sixty-six cases of PASH confirmed by CNB or surgical
excision in 61 patients because of five patients had
bilateral PASH. Their characteristics are presented in
Table 1. Median follow-up duration was 32 months (range,
6e114 months). All patients were women, with a median
age of 41 years (range, 14e61 years). Four patients had
post-menopause status and one was on hormone
replacement therapy at the time of PASH diagnosis. The
medical and medication histories of the participants were
unremarkable, with the exception of 12 (19.6%) patients,
who were taking levothyroxine for the management of
hypothyroidism or were following bilateral thyroidectomyfor thyroid cancer. Seven patients had a prior history of
breast disease, and among them two patients had a his-
tory of breast malignancy, both of whom were on ongoing
tamoxifen treatment prior to diagnosis of PASH. These
two patients underwent pathological examination for
diagnosis of newly developed suspicious findings on post-
operative follow-up imaging. For the majority of the pa-
tients, PASH lesions were identified during health
screening imaging tests, with no subjective symptoms.
However, a non-tender mass was palpable in most pa-
tients on physical examination.
Five patients had bilateral PASH, including PASH located
at bilateral accessory breasts in the axillary area in one
patient; four patients presented with significantly enlarged
bilateral breasts. In two of these latter four patients, the
rapid growth of the breast was associated with signs of
infection (redness, swelling, and localized sense of heat) on
physical examination at the time of the first hospital visit.
The prolactin level in one of these two patients rarely
exceeded the 100 ng/mL threshold; the patient had no
evidence of hypothyroidism and was neither pregnant nor
breast-feeding. This patient was treated conservatively for
breast infection, with signs of infection resolving within two
months, including a normalization of prolactin level.
Another patient was treated using bromocriptine, with
rapid growth and congestion resolving in both breasts
within one month. This initial treatment was changed to
tamoxifen for symptom relief. However, the patient did not
respond well to tamoxifen and redeveloped rapid growth





Median (IQR)a 32 (13, 52)
Age (years)
Median (IQR)a 41 (36, 46)
BMI









Health screening image test 33 (50%)
Subjective symptom 24 (36.4%)





Rapid growing huge breast 8 (12.1%)
Palpable mass 16 (24.2%)
Tenderness on physical examination
None 54 (81.8%)
Yes 12 (18.2%)







Subareolar area 7 (10.6%)
Upper outer quadrant 37 (56.1%)
Upper Inner quadrant 10 (15.2%)
Lower outer quadrant 5 (7.6%)
Lower Inner quadrant 5 (7.6%)
Accessary breast 2 (3.0%)
BMI body mass index, IQR interquartile range, PASH pseu-
doangiomatous stromal hyperplasia.
a The ShapiroeWilk test suggests that the data are not nor-
mally distributed.




Lesion size by diagnostic sonogram
Median (IQR)a 2.3 (1.3, 3.1)
Mammographic finding (N Z 43)
Normal 18 (41.9%)
Circumscribed mass 7 (16.3%)
Lobulated mass 10 (23.3%)
Focal asymmetry density 3 (7.0%)
Calcification 5 (11.7%)












Breast MRI finding (N Z 12)
Mass enhancement 9 (75.0%)
Non-mass enhancement 3 (25.0%)
Breast MRI Category (N Z 12)
BI-RADS 2 2 (16.7%)
BI-RADS 3 3 (25.0%)
BI-RADS 4a 5 (51.7%)
BI-RADS 4b 2 (16.7%)
PASH pseudoangiomatous stromal hyperplasia, BI-RADS breast
imaging-reporting and data system, MRI magnetic resonance
imaging.
a The ShapiroeWilk test suggests that the data are not nor-
mally distributed.
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tamoxifen treatment.3.2. Image findings of PASH
US, MMG, and MRI were performed on all, 43, and 12 cases,
respectively (Tables 2 and 3.). The median lesion size on US
was 2.3 cm (range, 0.6e14 cm), with generally benign
features of the shape and margins of the mass. BI-RADS
category 4a or 4b findings on US, indicative of a low-to-
moderate suspicion of malignancy, were identified in51.5% of cases. Microcalcifications in the PASH lesion were
identified in five cases on MMG. A BI-RADS category of 3
was reported in about 80% of patients who had MMGs. The
distribution of BI-RADS category score by US and MMG is
presented in Table 3. MRI was performed in 12 cases,
including five patients in whom PASH was diagnosed inci-
dentally on MRI during preoperative evaluation for a ma-
lignancy, three patients who underwent MRI due to
significant enlargement of bilateral breasts, and one pa-
tient who was undergoing routine follow-up after contra-
lateral mastectomy for malignancy. The MRI finding of three
patients with enlarging bilateral breasts was PASH-specific.
Multiple delineated and heterogeneous nodules were
identified on MRI, with edematous changes and replace-
ment of stromal tissue observed on T2 short tau inversion
recovery image.
3.3. Diagnosis and treatment
A PASH diagnosis was confirmed incidentally (when the
actual histological examination was performed for another




Sonographic BI-RADS Category Total
1 2 3 4a 4b
1 0 0 9 7 2 18 (41.9%)
2 0 0 6 3 1 10 (23.3%)
3 0 0 4 2 1 7 (16.3%)
4a 0 0 2 3 2 7 (16.3%)
4b 0 0 0 1 0 1 (2.3%)
Not done 0 0 11 12 0 0






The kappa value of the mammogram and ultrasonogram BI-RADS
score among patients who underwent mammography is 0.13 (p-
value Z 0.51).
BI-RADS breast imaging-reporting and data system.
Pseudoangiomatous stromal hyperplasia does not require surgery 739breast lesion) in nine cases (13.6%), with four of these cases
being benign and the other five being malignant. Five cases
(diagnosed by mastectomy) underwent subcutaneous mas-
tectomy with immediate reconstruction without patholog-
ical confirmation, because of clinical diagnosis of bilateral
PASH based on specific MRI finding and clinical feature of
significantly enlarged bilateral breasts. Subsequent to CNB,
due to indeterminate findings on US examination, only one
patient among four with significantly enlarged bilateral
breasts underwent subcutaneous mastectomy with imme-
diate reconstruction. CNB was performed in 61 cases, with
confirmation of PASH by CNB made in 39 (63.9%) of these
cases. In the other 22 cases (36.1%), the diagnosis of PASH
was confirmed on subsequent surgical excision or VAE. The
pathologic report of PASH after final treatment, including
CNB results of 17 cases without progression in the CNB-
positive group, is presented in Table 4.
The first treatment option for PASH was determined by
physician’s preference based on CNB results, imaging, and
clinical presentation. The treatment was subdivided into
observation (routine surveillance), VAE, or surgicalTable 4 Pathologic diagnosis after the final treatment.
Pathologic finding No. (%)
(N Z 66)
PASH 29 (43.9%)
Apocrine metaplasia with PASH 2 (3.0%)
Fibroadenomatoid hyperplasia with PASH 5 (7.6%)
Fibrocystic change with PASH 7 (10.6%)
Fibroadenoma with PASH 17 (25.8%)
IDP with PASH 3 (4.5%)
ADH with PASH 2 (3.0%)
LCIS with PASH 1 (1.5%)
Core needle biopsy results are the pathologic results in patients
with observation after confirmation of pseudoangiomatous
stromal hyperplasia.
PASH pseudoangiomatous stromal hyperplasia, IDP intraductal
papilloma, ADH atypical ductal hyperplasia, LCIS lobular carci-
noma in situ.excision, including mastectomy. The progression rate ac-
cording to first treatment method is presented in Table 5.
One patient in the observation group had adjuvant
chemotherapy for breast malignancy, with resultant
decrease in the size of the PASH lesion. There were three
cases of a proliferative lesion with atypia that were iden-
tified on final treatment; in all 3 cases, a lesion other than
PASH was confirmed on CNB. Progression was confirmed in
11 cases (16.6%) and median progression period was 26
months (range, 6e36 months) after the first treatment. On
univariate logistic regression analysis for progression, the
CNB results, symptoms, and lesion size were identified as
factors associated with progression after the first treat-
ment (Table 6). On multivariate logistic regression analysis,
after adjusting for CNB results, symptoms, and lesion size
were regarded as independent factors for progression. Of
note, multicollinearity, with variance inflation factor, was
not detected on this multivariate regression model. The
HosmereLemeshow test of goodness-of-fit was not signifi-
cant (P value Z 0.676). The AUC for this multivariate
analysis was 0.78 (95% CI, 0.68e0.88).4. Discussion
In our cohort, PASH was largely diagnosed in women of
reproductive age. It was detected during health screening
imaging tests; the patients had no subjective symptoms and
presented with palpable non-tender mass on physical ex-
amination. The clinical presentation widely varied, from
asymptomatic lesion to significantly enlarged bilateral
breasts. The findings on US and MMG were nonspecific, and
63.9% (39/61) had pathological confirmation of PASH by
CNB. The local progression rate of PASH after the first
treatment was 16.6% (11/66), with progression being asso-
ciated with CNB results, lesion size, and symptoms.
The estimated incidence rate of PASH varied from 0.4%
to 23.0% in several studies.10,11 This range of incidence rate
might reflect the disparate administration of pathological
diagnosis across different centers. A relatively high number
of PASH cases in our center reflects the nature of our hos-
pital as being a tertiary care center for the treatment of
breast cancer patients. The threshold for using CNB was
lower among breast cancer patients who undergo preop-
erative imaging assessment or follow-up surveillance after
treatment. Generally, the majority of PASH lesions detec-
ted on MMG or US were under the threshold for proceeding
with CNB. In our center, a few patients with PASH, with
probably benign findings on image study, underwent CNBTable 5 Follow-up data after the first treatment.
First treatment No. (%) Stable
disease
Progression p-value
(N Z 66) (N Z 55) (N Z 11)
Observation 20 (30.3%) 17 (85%) 3 (15%) 0.58
VAE 11 (16.7%) 8 (72.7%) 3 (27.3%)
Excision 29 (43.9%) 24 (82.8%) 5 (17.2%)
Mastectomy 6 (9.1%) 6 (100%) 0
VAE vacuum-assisted excision.
Table 6 Univariate and multivariate analyses of the progression of PASH.
Variables Univariate Multivariate
OR (95% CI) P value OR (95% CI) P value
Pathology result by CNB
Diagnosis PASH ref ref
Diagnosis other than PASH 29.2 (3.4e252.3) 0.01 13.6 (1.9e94.3) 0.01
Symptom
None ref ref
Rapid growing huge breast 0.4 (0.1e9.4) 0.57 0.5 (0.1e9.2) 0.70
Palpable mass enlargement 5.4 (1.3e21.3) 0.02 6.1 (1.4e21.6) 0.01
Lesion size by diagnostic US
 3 cm ref ref
> 3 cm 4.3 (1.2e21.9) 0.04 2.8 (0.4e16.9) 0.24
First treatment method
Surgical excision ref ref
VAE 1.1 (0.2e4.9) 0.94 1.8 (0.4e8.9) 0.89
Observation 2.3 (0.4e11.5) 0.33 2.4 (0.1e94.4) 0.75
PASH pseudoangiomatous stromal hyperplasia, CNB core needle biopsy, US ultrasonography, VAE vacuum-assisted excision, ref refer-
ence, OR odds ratio, CI confidence interval.
740 K.H. Yoon et al.during the preoperative evaluation period for another
lesion. It is possible that wide application of CNB increased
the incidence rate of PASH. Because of the possibility that
pathologic examination may not have been performed for
actual PASH lesions, the incidence rate of PASH is difficult
to be fully clarified based on our data.
The etiology and pathophysiology of PASH are unclear,
but a hormone-dependent stromal change is widely
accepted as being causative.14 The hormonal etiology is
supported by the following evidence: the expression of
progesterone receptor on the nuclei of myofibroblasts in
PASH lesions, the high prevalence of premenopausal women
among patients with PASH, and a case report that associ-
ated reduction in PASH progression with tamoxifen.15 Other
hypotheses include an abnormal proliferation of lymphatic
channels, based on electron microscopy findings.16 Another
hypothesis is that PASH is an independent myofibroblastic
lesion of the breast.17 In our study cohort, PASH developed
in two women with the use of tamoxifen as an adjuvant
endocrine therapy. Hypothyroidism was observed in 12 of
our 61 patients. Signs of infections were observed in a few
patients with significantly enlarged bilateral breasts, with
these signs being relieved with bromocriptine treatment. It
is known that prolactin is an essential hormone for normal
production of breast milk and that it promotes normal
breast proliferation and differentiation.18 Hyperthyroidism
induces subsequent hyperprolactinemia. Hyper-
prolactinemia leads to the accumulation of the static
secretion and nuclear factor kappa-light-chain-enhancer of
the activated B cells (NF-kB) signaling pathway, which
triggers an inflammatory response in mammary epithelial
cells.19 Based on this evidence, we suggest that prolactin
might also be associated with the development of PASH.
PASH might mimic fibroadenoma, as well as co-exist with
other breast lesions. Therefore, PASH could present with a
wide spectrum of clinical and radiological manifestations.
There were no specific findings on US and MMG in our data.
However, patients with significantly enlarged bilateral
breasts had PASH-specific MRI finding and clinicalpresentation. In our experience, these specific conditions
of PASH were not necessary for CNB for diagnosis of PASH.
CNB was indicated only for another suspicious finding that
indicated a lesion other than PASH on imaging finding.
Traditionally, surgical excision is recommended for
confirmation of occult malignancy. In our dataset, a pre-
malignant lesion that combined with PASH was identified in
three cases. All three cases were in the CNB-negative
group, with confirmation of atypical ductal hyperplasia
(ADH), and lobular carcinoma in situ by CNB, respectively.
PASH was diagnosed by surgical excision, with PASH forming
only a small portion of the premalignant mass. In the CNB-
positive group, there was no evidence of underestimation
of an angiosarcoma for PASH.
Although PASH is a benign breast disease, it can prog-
ress. CNB results, enlargement of a palpable mass, and
>3 cm on US were associated with progression. The AUC for
multivariate analysis was 0.78 (95% CI, 0.68e0.88), indica-
tive of a relatively good predictive power of the factors.
Selected cases associated with progression should be
considered for surgical excision of PASH lesions for symp-
tomatic relief or cosmetic effect.
There are several limitations to our study. First, this is a
retrospective study. Our data were affected by possible
selection bias. We included only cases with at least 6
months follow-up after PASH diagnosis. Furthermore, data
were uncertain with regard to the accuracy of medical re-
cords. Second, although factors associated with PASH can
be identified in this design, a cause-and-effect relationship
cannot be determined. Serum prolactin levels were only
available for patients with a diagnosis of hypothyroidism;
therefore, the possible relationship between PASH and
prolactin requires further research. Third, PASH can coexist
with other breast lesions; it is possible that the progression
may be triggered by a coexisting lesion. To lower this
possible effect, we defined progression as an increase in
the volume of a lesion after diagnosis or the first treatment,
with the diagnosis of PASH confirmed for progressive lesions
by surgical excision or VAE.
Pseudoangiomatous stromal hyperplasia does not require surgery 741In conclusion, PASH is a benign mesenchymal prolifera-
tive lesion of the breast. Our findings indicate that CNB is
sufficient to confirm diagnosis of PASH what is necessary for
an abnormal imaging or physical examination finding. Sur-
gical modalities may not be indicated to rule out occult
malignancy after a diagnosis of PASH by CNB. The pro-
gression of PASH was associated with lesion size (>3 cm),
enlargement of palpable mass, and a diagnosis other than
PASH on CNB. Surgical excision or VAE or close monitoring
are required to manage progression of PASH. Furthermore,
surgery might be helpful in PASH with bilateral huge
breasts. With regard to treatment method, the modality
may be selected based on evidential data, surgeon’s pref-
erence, or patient’s need.
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